CoChat

Inhibitory G proteins and their receptors: emerging therapeutic targets for obesity and diabetes

Open access
Kimple, Michelle E, Neuman, Joshua C, Linnemann, Amelia K, Casey, Patrick J · 2014 · Experimental & Molecular Medicine
Cited by 55

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

The worldwide prevalence of obesity is steadily increasing, nearly doubling between 1980 and 2008. Obesity is often associated with insulin resistance, a major risk factor for type 2 diabetes mellitus (T2DM): a costly chronic disease and serious public health problem. The underlying cause of T2DM is a failure of the beta cells of the pancreas to continue to produce enough insulin to counteract insulin resistance. Most current T2DM therapeutics do not prevent continued loss of insulin secretion capacity, and those that do have the potential to preserve beta cell mass and function are not effective in all patients. Therefore, developing new methods for preventing and treating obesity and T2DM is very timely and of great significance. There is now considerable literature demonstrating a link between inhibitory guanine nucleotide-binding protein (G protein) and G protein-coupled receptor (GPCR) signaling in insulin-responsive tissues and the pathogenesis of obesity and T2DM. These studies are suggesting new and emerging therapeutic targets for these conditions. In this review, we will discuss inhibitory G proteins and GPCRs that have primary actions in the beta cell and other peripheral sites as therapeutic targets for obesity and T2DM, improving satiety, insulin resistance and/or beta cell biology. G proteins and their receptors provide potential drug targets for treating type 2 diabetes and obesity. In a review article, a team led by Michelle Kimple of the University of Wisconsin-Madison, USA, discusses the role of guanine nucleotide-binding proteins (G proteins) and G protein-coupled receptors (GPCRs) in the pancreatic beta-cell, which secretes insulin, and in other tissues that respond to insulin. The GPCRs are a large group of membrane proteins that respond to molecules outside the cell and activate responses inside the cell. The researchers highlight several specific GPCRs that animal or human studies have indicated might be particularly suitable as therapeutic targets for diabetes or obesity. These include the EP3 receptor, the α2A adrenergic receptor, the MT2 receptor and the CB1 receptor. Further research into these proteins may yield new therapies, conclude the authors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/emm.2014.40

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

Metadata

Authors
Kimple, M. E., Neuman, J. C., Linnemann, A. K., & Casey, P. J.
Venue
Experimental & Molecular Medicine
Published
2014-06-20
Volume
46
Issue
6
Pages
e102-e102
ISSN
  • 1226-3613 (ISSN-L)
  • 2092-6413
OpenAlex
W1967031212
Cited by
55
References
22
FWCI
2.56
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.